Kornimate/medical-research-clean huggingface dataset:
use of a hypercaloric and hyperprotein supplement enriched with immunonutrients in multi-pathological malnourished patients to improve the incidence and prevalence of pressure sores

Conditions: Multimorbidity; Comorbidity; Malnutrition; Pressure Ulcer Prevention

Summary: the goal of this study is to evaluate the efficacy of a hypercaloric, hyperproteic enteral formula enriched with immunonutrients in preventing and treating pressure injuries in hospitalized malnourished patients. participants will take enteral formula (a complete hyperproteic and hypercaloric oral nutritional supplement with a fibre mixture enriched in omega 3, l-arginine and nucleotides, providing vitamin c and zinc) or a hyperproteic and hypercaloric oral nutritional supplement with fibre mixture every day for 30 days.


Eligibility criteria:
inclusion criteria: * hospitalized chronic patients with complex needs in the internal medicine department of a regional hospital. * malnourished or at risk of malnutrition. * moderate-high risk of developing pressure-related injuries or the presence of pressure-related injuries. exclusion criteria: * limitations in oral intake (due to pathologies, state of health, among others). * contraindications for using the oral route and digestive intolerance or allergy to any of the components of the products.

Keywords: multimorbidity comorbidity malnutrition pressure ulcer supplements immunonutrients
silymarin's advantage on graft effectiveness

Conditions: Posttransplant Diabetes Mellitus; Acute Graft Rejection; Biopsy Proven Acute Rejection; Antibody Mediated Rejection of Kidney Transplant; Arterial Hypertension, Chronic Kidney Disease

Summary: the study examines the impact of silymarin supplementation during the early post-transplant period, administering 900 g daily for 30 days under standard treatment. subsequently, the investigators investigate its impact on graft function, as measured by egfr (ckd-epi equation), uacr or upcr, the development of dndsa, rejection changes, and histological changes in the 3-month biopsy protocol. at the same time, investigators will investigate the effect of silymarin on metabolic complications-ptdm, dlp, disorders of calcium-phosphate metabolism, and arterial hypertension in the post-transplant period-in comparison with the placebo group. at the same time, investigators will investigate the safety and tolerance of silymarin.


Eligibility criteria:
inclusion criteria: * first or second kidney transplant recipient * deceased or living donor kidney transplant * patients receiving standard immunosuppression regimen: * tacrolimus or cyclosporine + mycophenolate mofetil + corticosteroids * body mass index (bmi) 18-35 kg/m² * willingness to provide informed consent * ability to understand and comply with study procedures * stable medical condition without significant comorbidities exclusion criteria: * multi-organ transplant recipients * recipients of abo-incompatible or highly sensitized transplants * active infectious complications at the time of transplantation: hiv, active hepatitis b or c, active cytomegalovirus (cmv) infection * patients with known liver disease: cirrhosis, active hepatitis, alt or ast \> 2.5 times the upper limit of normal * significant cardiovascular disease: recent myocardial infarction (within 6 months), unstable angina, severe heart failure (nyha class iii or iv) * malignancy within the past 5 years (except successfully treated non-melanoma skin cancer) * current or recent (within 30 days) participation in another clinical trial * pregnancy or planned pregnancy during the study period * known allergy or hypersensitivity to silymarin or milk thistle * patients taking medications with significant interactions with silymarin: anticoagulants, cytochrome p450 enzyme modulators * psychiatric conditions that may interfere with study compliance * uncontrolled diabetes mellitus (hba1c \> 8.5%) * history of non-compliance with medical treatment * patients with known genetic disorders affecting drug metabolism

Keywords: silymarin biopsy proven acute rejection dndsa ptdm protocolar biopsy kidney transplantation
pilot study about extra virgin olive oil "coratina" in mild cognitive impairment and alzheimer's disease patients

Conditions: Neurodegenerative Diseases

Summary: alzheimer's disease is a neurodegenerative disease age related caused by neurofibrillary tangles misfolding and beta-amyloid protein accumulation. in the last decade several findings showed the role of biophenols present in diary intake such as extra virgin olive oil as potential antagonist of neurodegeneration. two population studies (the seven countries study and three-city-study) and four clinical trials (predimed, predimed - navarra, actrin and isrctn) have already suggested that mediterranean diet or other diets supplemented with extra virgin olive oil could improve cerebral performance.

24 mci or alzheimer's disease patients will be recruited and randomised; 12 of them will receive extra virgin olive oil "coratina" (evoo-c); 12 of them will receive biophenol low dose olive oil (roo). each patient will consume a total amount of 10 mg olive oil in a year (12 months). clinical assessement will be based on: * neurological examination (t0, t6, t12); * cardiological examination (t0, t12): a supra-aortic vessels and brachial artery ecocolordoppler will be performed; * ophthalmological evaluation (t0, t12): a optic coherence tomography will be performed; * neuropsychological assessment (t0, t12); * nutritional assessement(t0, t3, t6, t9, t12). each subject will perform: * brain mri (t0, t12); * beta amyloid positron emission tomography (t0, t12) a lumbar puncture will be ruled as well (t0) and markers of neurodegeneration (beta-amyloid 1 - 42, total tau protein, fosfo-tau, brain derived neurotrophic factor (bdnf), neurofilament (nfl) will be quantified); renal, hepatic and nutritional status will be assessed 3 times in 12 months (t0, t6, t12).

Eligibility criteria:
inclusion criteria: * mci diagnosis in the last month prior the recruitment; * clinical dementia rating scale - global score (cdr - gs) 0,5 and mini mental examination 24 - 27; exclusion criteria: * smoke; * hypertension; * diabetes; * positive history of stroke, epilepsy or cardiac disease; * bmi \> 30; * depression or other psychiatric disturbances; * low compliance to medical interventions; * positive history of olive oil allergy or intolerance; * positive history of chronic inflammatory intestinal disease or malabsorption; * positive history of maculopathy or retinopathy; * mri leukoaraiosis ii-iii grade fazekas or mri lacunar infarctions

Keywords: mild cognitive impairment alzheimer's disease extra virgin olive oil
comparison of two resurfacing prostheses in the treatment of osteoarthritis of the shoulder

Conditions: Osteoarthritis

Summary: the purpose of this study is to determine whether there is a difference between the result of treatment of shoulder osteoarthritis with two different shoulder prostheses.

in this randomized study, we wish to investigate with the use of clinical and radiological parameters whether there is a difference between the result of treatment of shoulder osteoarthritis with the copeland resurfacing prosthesis and the global cap resurfacing prosthesis. clinical parameters with the help of the constant shoulder score (css) and western ontario osteoarthritis of the shoulder index (woos): 1. pain 2. activities of daily living (adl) 3. range of motion (rom) 4. muscle strength radiologic parameters: 1. migration of resurfacing prostheses with use of mb-rsa 2. bone density around the prosthesis measured with dual energy x-ray absorptiometry (dexa) 3. correlation between bone density and prosthesis migration

Eligibility criteria:
inclusion criteria: 1. patients with shoulder osteoarthritis with cartilage defect of the caput humeri and not the glenoid cavity 2. aged 18 years or older and fit 3. informed, written consent - exclusion criteria: 1. patients found unsuitable preoperatively for a resurfacing prosthesis 2. patients aged 85 or older 3. patients with rheumatoid arthritis 4. patients who previously had undergone shoulder alloplasty or other major shoulder surgery (more than just diagnostic arthroscopy) 5. patients unable to avoid nsaid after surgery 6. patients requiring regular systemic steroid treatment 7. female patients taking hormone substitution 8. patients with metabolic bone disease 9. severe shoulder instability with large rotator cuff defect ( will often necessitate special prosthesis components or even major soft-tissue surgery) 10. female patients in the fertile age range who do not use safe anti-conception (oral contraception, intrauterine devices, depot gestagens, vaginal hormone rings) -

Keywords: osteoarthritis shoulder resurfacing prosthesis
improvement of anxiety management during a venous puncture about children with a participatory entertainment method

Conditions: Anxiety Disorders

Summary: the purpose of this study is to demonstrate an anxiety decrease about children 3 to 6 years during a venous puncture with the "fabrique à histoire".

the purpose of this study is to demonstrate an anxiety decrease about children 3 to 6 years during a venous puncture with the "fabrique à histoire". the study will compare the "fabrique à histoire"(lunii(r)) with the usual care.

Eligibility criteria:
inclusion criteria: * children 3 to 6 years in pediatric emergency needing to venous puncture * oral consent by children * informed and signed consent by tenured of parent authority * to have anaesthetic patch 45 minutes or more before the venous puncture exclusion criteria: * to have anaesthetic patch less than 45 minutes before the venous puncture because of necessity to blood test or an other emergency * necessity to analgesic 3 emergency * necessity to meopa * minor parents * assessment of anxiety is not possible because of comorbidity * anterior participation to these study

Keywords: anxiety children
the efficacy and mechanism of acupuncture treatment in patients with subjective cognitive decline

Conditions: Subjective Cognitive Decline; Subjective Cognitive Complaint

Summary: this study evaluates the efficacy and mechanism of acupuncture treatment in patients with subjective cognitive decline. half of patients will receive acupuncture treatment for 12 weeks, while the other half will receive sham acupuncture treatment for 12 weeks .


Eligibility criteria:
inclusion criteria: 1. male and female adults aged 55-75; 2. native chinese speakers with right-handed and at least a primary school education; 3. self-reported persistent memory decline, which was confirmed by caregivers; 4. normal general cognitive function and not meeting the criterion of mild cognitive impairment, as defined by performance within the normal range on both measures within at least one cognitive domain or in each of the three cognitive domains sampled (adjusted for age and education); 5. no or minimal impairment in activities of daily living; exclusion criteria: 1. presence of positive neurologic history (e.g., traumatic brain injury, stroke, parkinson's disease, multiple sclerosis, etc.) ; 2. treatments that would affect cognitive function; 3. presence of significant psychiatric history (e.g., bipolar disorder, schizophrenia, etc.) and/or severe anxiety and depression; 4. presence of serious heart, kidney, liver, gastrointestinal, infectious, endocrine disease or cancer; 5. history of alcohol or drug abuse/addiction in nearly two years; 6. any contraindications for magnetic resonance imaging (mri) scans (e.g., aneurysm clip pacemaker, etc.); 7. significant visual and/or auditory impairment uncorrected by aids, and unable to perform neuropsychological evaluations; 8. currently enrolled in another research study; 9. received acupuncture treatment in the preceding month.
conjunctival swab vs nasopharyngeal swab in patients with covid-19

Conditions: COVID-19; SARS-CoV 2

Summary: the aim of this possible study is to identify if sars-cov-2 can be found in the tear film and conjunctiva of a patient with covid-19.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * a confirmed covid-19 disease * signed and dated declaration of consent * the patient fell ill in tyrol exclusion criteria: * none
evaluation of 5-[123i]-a-85380 and spect imaging in individuals with parkinsons disease

Conditions: Parkinson Disease

Summary: the underlying goal of this study is to assess \[123i\] 5-ia and spect imaging as a tool to detect nicotinic receptor activity in the brain of pd patients. all study procedures will be conducted at the institute for neurodegenerative disorders (ind) and molecular neuroimaging (mni) in new haven, ct. approximately 10 patients with a diagnosis of pd without cognitive changes will be recruited to participate in this study. patients will be eligible to participate if they have a diagnosis of pd of more than 2 years duration and have no significant cognitive changes.

all subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the mmse, the anam computerized cognitive battery, and other tests of executive function. all subjects will be evaluated with united parkinson disease rating scales (updrs) following an overnight withdrawal of anti-parkinson medication. subjects will be asked to undergo an injection of \[123i\] 5-ia followed by spect imaging as described below. a second \[123i\] 5-ia and spect imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial \[123i\] 5ia imaging session. the primary imaging outcome measure will be vt', the equilibrium distribution volume in brain regions is determined from an mri-directed region-of-interest (roi) analysis. the baseline imaging vt' will be compared to the follow-up imaging study to the reliability of the nicotinic \[123i\] 5-ia imaging.

Eligibility criteria:
inclusion criteria: * the presence of idiopathic parkinson disease * a clear clinical response to dopaminergic therapy treatment * hoehn and yahr stages \< 3; * 2-7 year duration from time of diagnosis. * mini-mental status exam score of \>24, * for females, non-child bearing potential or negative urine pregnancy test on day of \[123i\] 5-ia injection. exclusion criteria: * secondary parkinsonism; * nicotine dependence or use within the previous 12 months prior to enrollment; * treatment with aricept (donepezil), exelon (rivastigmine), cognex (tacrine) within the past 30 days; treatment with medications that bind to the nicotinic receptor. * clinically significant clinical laboratory value and/or medical or psychiatric illness; * mini-mental status exam score of ≤24. * the subject has evidence of clinically significant thyroid disease, gastrointestinal, cardiovascular, hepatic, renal, hematologic, neoplastic, endocrine, neurologic, immunodeficiency, pulmonary, or other medical or psychiatric disorder; * the subject has received an investigational drug within 30 days of the screening visit; * pregnancy

Keywords: parkinson imaging nicotinic receptors
dibenzyl trisulphide (guineahen weed) for stage iv cancer

Conditions: Stage IV Prostate Cancer; Stage IV Colon Cancer; Stage IV Breast Cancer; Stage IV Cancer of the Cervix

Summary: this study is being done to find the effect of dibenzyl trisulphide (active ingredient in guinea hen weed in combination in patients with stage four cancer of the breast, prostate, cervix and colon.

there have been many claims of the value of guinea hen weed in the treatment of different cancers. the preparation is readily available and used locally. the team proposes to validate the studies done on cancer cell lines by conducting a clinical trial to determine the clinical benefit in advanced and metastatic cancers.

Eligibility criteria:
inclusion criteria: * age: greater than 12 years. * documented histologic evidence of cancer * staged as stage iv * world health organization (who) performance status of between 0 and 2 * radiological confirmation of metastases with bone scan or x ray, ct and/or mri scan exclusion criteria * cancer stages less than stage 4 * pregnant women * children 0 - 12 years
a comparative study of khk6188

Conditions: Postherpetic Neuralgia

Summary: this is a placebo-controlled, double blind, crossover study to evaluate the efficacy and safety of khk6188 in postherpetic neuralgia when administered orally for 2 weeks.


Eligibility criteria:
inclusion criteria: * patients with pain for ≥ 3 months and ≤ 1 year following onset of a herpes zoster rash * patients with a mean pain intensity score (11-point numerical rating scale) of ≥ 4 * patients whose rash has been healed * patients who are able to fill their patient diary * patients who provided written voluntary informed consent to participate in the study exclusion criteria: * patients who have other pain or disease which may impair the self assessment of pain * patients who have dementia, depression or schizophrenia which may affect the self assessment of pain * history or presence of severe cardiovascular disease, hepatic dysfunction, renal failure, respiratory disease, blood disease or cns disorder * history or presence of a drug allergy * patients who have a history of a diagnosis of cancer or a treatment of cancer within 5 years prior to the study entry * patients received an investigational medication within 4 months (6 months for biologic medication such as antibody) prior to the informed consent * women of child bearing potential who do not agree to avoid pregnancy from the time of providing the consent until 3 months after the end of dosing, or men of reproductive potential who do not agree to avoid pregnancy from the time of the first dose until 3 months after the end of dosing * patients who are pregnant, lactating, or possibly pregnant * patients judged to be inappropriate to enter the study by a investigator or a subinvestigator
optical elastography of systemic sclerosis skin

Conditions: Scleroderma

Summary: the goal of this study is to develop a new way to assess skin thickness in patients with scleroderma (systemic sclerosis). the study will test how well a new imaging method called optical coherence elastography (oce) compares to the current clinical method used to estimate skin thickness, the modified rodnan skin score (mrss).


Eligibility criteria:
inclusion criteria for scleroderma patients: * meet the 2013 american college of rheumatology and the european league against rheumatism (acr/eular) criteria for systemic sclerosis with limited or diffuse cutaneous involvement exclusion criteria: * have another skin disease other than systemic sclerosis
feasibility of measuring skin carotenoid level in an asthma clinic

Conditions: Asthma

Summary: the purpose of this study is to assess the use of a practical tool to objectively measure the fruit and vegetable intake in people with asthma.

after consenting to join the study, all participants enter a single cohort, cross-sectional study to assess pulmonary function, asthma control, carotenoid level, and diet intake.

Eligibility criteria:
inclusion criteria: * pulmonary patients 18 years of age and older * confirmed diagnosis of asthma by a physician and confirmed by a pulmonary physician * english speaking * access to the internet exclusion criteria: * acute upper or lower respiratory infection * systemic corticosteroids * recent or current confirmed diagnosis of covid-19
dynamic knee laxity measurement coupled to mri in cases of suspected partial anterior cruciate ligament tear

Conditions: Anterior Cruciate Ligament Tear

Summary: anterior cruciate ligament (acl) tear is frequent, but the diagnosis of partial tears is difficult. standard mri may be used but is of limited diagnostic value. the present study aimed to evaluate the diagnostic interest of dynamic knee laxity measurement coupled to mri for the diagnosis of acl tear.


Eligibility criteria:
inclusion criteria: * knee injury requiring mri examination * accepting to participate * covered by a health care insurance system exclusion criteria: * mri contraindication * pregnancy * patient included in another study potentially affecting the results * protected patients

Keywords: dynamic knee laxity measurement laxi-mri partial anterior cruciate ligament tear
comparative clinical study to evaluate the efficacy and safety of rosuvastatin vs coq10 on nonalcoholic steatohepatitis

Conditions: Nonalcoholic Steatohepatitis

Summary: this study will be a randomized, controlled, parallel study that aims to evaluate the efficacy and safety of rosuvastatin versus coenzyme q10 on nonalcoholic steatohepatitis patients.

* this study will be a randomized, controlled, parallel study. * it will be conducted on 46 patients diagnosed with nash * the patients will be randomized into two groups: group 1(n=23): patients will receive rosuvastatin 20mg/day orally group 2(n=23): patients will receive coenzyme q10 100 mg/day orally the patients will be selected from community awareness campaigns about nash in alexandria , egypt . written informed consent will be obtained from all patients. this study will be approved by the research ethics committee of tanta university and alexandria university. the study duration will be 3 months.

Eligibility criteria:
inclusion criteria: * age: ≥ 18 years. * gender: both male and female patients will be included. * patients have established diagnosis of nash (based on liver ultrasonography). exclusion criteria: * young ages \<18 years * secondary causes of hepatic fat accumulation such as significant alcohol consumption as defined by an average daily consumption of alcohol greater than 30 g/day in men and greater than 20 g/day in women or long-term use of a steatogenic medication (e.g., non-steroidal anti-inflammatory drugs (nsaids) amiodarone, methotrexate, tamoxifen, corticosteroids) * patients with a known history of viral hepatitis, hemochromatosis, wilson's disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction. * patients with inflammatory diseases. * subjects using any other lipid-lowering agents, or any supplements known to have antioxidant activity and omega-3 supplementation for at least 3 months before participation in the trial * current pregnancy * breastfeeding * females on oral contraceptive pills * patients with renal impairment * patients with heart failure * patients with cancer or with a history of cancer treatment * any contraindications to coenzyme q 10 or statins like hypersensitivity to anyone * patients with predisposing risk factors for myopathy/rhabdomyolysis.

Keywords: nonalcoholic steatohepatitis nash nafld non-alcoholic fatty liver disease rosuvastatin coenzyme q10 fatty liver statin liver diseases